FR18C0004I2 - Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux - Google Patents

Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux

Info

Publication number
FR18C0004I2
FR18C0004I2 FR18C0004C FR18C0004C FR18C0004I2 FR 18C0004 I2 FR18C0004 I2 FR 18C0004I2 FR 18C0004 C FR18C0004 C FR 18C0004C FR 18C0004 C FR18C0004 C FR 18C0004C FR 18C0004 I2 FR18C0004 I2 FR 18C0004I2
Authority
FR
France
Prior art keywords
benzothiophene
treatment
mental disorders
substitute piperazine
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C0004C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C0004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of FR18C0004I1 publication Critical patent/FR18C0004I1/fr
Application granted granted Critical
Publication of FR18C0004I2 publication Critical patent/FR18C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR18C0004C 2005-04-14 2018-09-18 Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux Active FR18C0004I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116698 2005-04-14
PCT/JP2006/308162 WO2006112464A1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Publications (2)

Publication Number Publication Date
FR18C0004I1 FR18C0004I1 (fr) 2018-11-02
FR18C0004I2 true FR18C0004I2 (fr) 2021-01-22

Family

ID=36645750

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C0004C Active FR18C0004I2 (fr) 2005-04-14 2018-09-18 Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux

Country Status (28)

Country Link
US (14) USRE48059E1 (oth)
EP (1) EP1869025B3 (oth)
KR (1) KR100937623B1 (oth)
CN (1) CN101155804B (oth)
AR (1) AR053577A1 (oth)
AT (1) ATE496911T3 (oth)
AU (1) AU2006237905C1 (oth)
BE (1) BE2018C037I2 (oth)
BR (1) BRPI0609785B8 (oth)
CA (1) CA2602247C (oth)
CY (2) CY1111206T1 (oth)
DE (1) DE602006019838D1 (oth)
DK (1) DK1869025T6 (oth)
ES (1) ES2358631T7 (oth)
FR (1) FR18C0004I2 (oth)
HU (2) HUE011611T6 (oth)
IL (1) IL185909A (oth)
IN (1) IN2012DN00855A (oth)
LT (1) LTC1869025I2 (oth)
LU (1) LUC00086I2 (oth)
MY (1) MY142746A (oth)
NL (1) NL300946I2 (oth)
PL (1) PL1869025T6 (oth)
PT (1) PT1869025E (oth)
SI (1) SI1869025T1 (oth)
TW (1) TWI320783B (oth)
WO (1) WO2006112464A1 (oth)
ZA (1) ZA200708686B (oth)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AU2007254244C1 (en) 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
KR101514846B1 (ko) 2006-05-18 2015-04-23 아레나 파마슈티칼스, 인크. ５-ｈｔ２ａ 세로토닌 수용체의 조절인자로서 유용한 페닐-피라졸의 결정질 형태 및 그의 제조 방법
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
AU2009214190A1 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
CA2713187C (en) 2008-02-22 2016-06-07 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2364142B1 (en) 2008-10-28 2018-01-17 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CA2797708C (en) 2010-05-04 2016-08-16 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EP2736894B1 (en) * 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b] thiophene compounds
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
CN104755082A (zh) 2012-10-25 2015-07-01 大塚制药株式会社 含有依匹唑派或其盐的用于与神经变性疾病相关的行为和精神症状或与精神疾病相关的冲动症状的预防和/或治疗剂
EP2792359A1 (en) * 2013-04-19 2014-10-22 Merz Pharma GmbH & Co. KGaA Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN104557896A (zh) * 2013-10-18 2015-04-29 沈敬山 布瑞哌唑、其关键中间体及其盐的制备方法
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US20170042887A1 (en) 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
CN105985314A (zh) * 2015-02-05 2016-10-05 苏州旺山旺水生物医药有限公司 布瑞哌唑类似物的制备方法
CN104844586A (zh) * 2015-04-16 2015-08-19 重庆医药工业研究院有限责任公司 一种依匹哌唑无定型物及其制备方法
CN104829588B (zh) * 2015-04-30 2017-03-29 苏州苏旺森生物医药科技有限公司 一种苯并[b]噻吩的制备方法及其中间体
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
CN105061414B (zh) * 2015-07-21 2019-01-01 杭州新博思生物医药有限公司 一锅法制备Brexpiprazole
WO2017025987A1 (en) 2015-08-11 2017-02-16 Mylan Laboratories Limited Process for the preparation of brexpiprazole
EP3150591A1 (en) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Process and intermediates for the preparation of benzo[b]thiophene compounds
CN106749219A (zh) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
CN105440026A (zh) * 2015-12-04 2016-03-30 上海勋和医药科技有限公司 依匹哌唑的制备方法
CN105461704A (zh) * 2015-12-15 2016-04-06 南京艾德凯腾生物医药有限责任公司 一种依匹哌唑的制备方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
CN106916148B (zh) * 2015-12-25 2021-07-06 上海科胜药物研发有限公司 一种合成依匹哌唑的方法
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
CN106938982A (zh) * 2016-01-05 2017-07-11 连云港皓海医药科技有限公司 布瑞哌唑的制备方法及用于制备布瑞哌唑的化合物
CN105399736B (zh) * 2016-01-07 2018-10-19 安徽省逸欣铭医药科技有限公司 一种依匹哌唑新的制备方法
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2017216661A1 (en) 2016-06-17 2017-12-21 Jubilant Generics Limited Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
WO2018033483A1 (en) 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
WO2018060916A1 (en) * 2016-09-28 2018-04-05 Alembic Pharmaceuticals Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
US11279696B2 (en) 2016-11-09 2022-03-22 Msn Laboratories Private Limited Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
WO2018141886A1 (en) 2017-02-02 2018-08-09 Hexal Aktiengesellschaft Crystalline brexpiprazole
WO2018172463A1 (en) 2017-03-22 2018-09-27 Amneal Pharmaceuticals Company Gmbh Process for the preparation of brexpiprazole
WO2019073481A1 (en) * 2017-10-12 2019-04-18 Indoco Remedies Limited PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND ITS INTERMEDIATES
SMT202100655T1 (it) 2017-12-14 2022-01-10 H Lundbeck As Trattamenti combinati che comprendono la somministrazione di 1h-pirazolo[4,3-b]piridina
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
CN110627777B (zh) * 2018-06-21 2021-01-26 中国科学院上海药物研究所 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
CN111320619A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物的杂质及用途
CN109970705B (zh) * 2019-05-14 2021-02-09 浙江工业大学 一种应用廉价金属铜制备依匹哌唑中间体及依匹哌唑的方法
JPWO2021029020A1 (oth) * 2019-08-13 2021-02-18
WO2021207532A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202216676A (zh) * 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2023011608A1 (zh) * 2021-08-05 2023-02-09 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
CN115772175A (zh) * 2021-09-07 2023-03-10 中国科学院分子细胞科学卓越创新中心 噻吩并环化合物及其制备方法和应用
CN114181202A (zh) * 2021-12-17 2022-03-15 湖南省湘中制药有限公司 一种依匹哌唑的制备方法
CN118580229B (zh) * 2024-08-07 2024-12-27 湖南一格制药有限公司 布瑞哌唑的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
DK574274A (oth) 1973-12-06 1975-07-28 Ciba Geigy Ag
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2827566A1 (de) 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
GB8704572D0 (en) 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FI920023A7 (fi) 1989-07-07 1992-01-03 Pfizer Heteroaryylipiperatsiiniyhdisteet antipsykootteina
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
CA2157348A1 (en) 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332B1 (en) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
CO4750663A1 (es) 1995-09-15 1999-03-31 Sanofi Synthelabo Derivados de quinolein-2 (1h)-ona, su preparacion y su aplicacion en terapeutica
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
CA2250347C (en) 1996-03-29 2006-02-21 Duphar International Research B.V. Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP0934932A4 (en) 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
AU4726699A (en) 1998-06-30 2000-01-17 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1188747B1 (en) 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
WO2001009126A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Serotonergic benzothiophenes
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
WO2001046179A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
IL157412A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10151569A1 (de) 2001-10-23 2003-04-30 Basf Ag Thermisch härtbare Bindemittel
AU2002353659A1 (en) 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
AP2005003250A0 (en) 2002-09-17 2005-03-31 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
JP2005539344A (ja) 2002-09-20 2005-12-22 オスラム　オプト　セミコンダクターズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 光学式の走査ヘッド及び該走査ヘッドの製造のための方法
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BRPI0305500B1 (pt) 2003-01-09 2018-01-23 Otsuka Pharmaceutical Co., Ltd. Processo para preparar aripiprazol
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
PT1626721T (pt) 2003-05-23 2017-02-28 Otsuka Pharma Co Ltd Derivados de carbostirilo e estabilizadores de humor para tratar distúrbios de humor
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GB0504203D0 (en) 2005-03-01 2005-04-06 Novartis Ag Organic compounds
AU2006224760A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline Type II aripiprazole
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
WO2007081366A1 (en) 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Wet granulation pharmaceutical compositions of aripiprazole
RU2470635C2 (ru) 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
US7968431B2 (en) 2008-07-15 2011-06-28 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
EP2736894B1 (en) * 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b] thiophene compounds
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
AU2006237905A1 (en) 2006-10-26
ZA200708686B (en) 2009-01-28
CA2602247A1 (en) 2006-10-26
US20130158044A1 (en) 2013-06-20
PL1869025T3 (pl) 2011-06-30
LTC1869025I2 (lt) 2019-05-10
DK1869025T6 (da) 2017-01-02
US20180214444A1 (en) 2018-08-02
BRPI0609785B8 (pt) 2021-05-25
TW200716619A (en) 2007-05-01
US20190321359A1 (en) 2019-10-24
WO2006112464A1 (en) 2006-10-26
BRPI0609785B1 (pt) 2020-10-20
BE2018C037I2 (oth) 2025-12-10
MY142746A (en) 2010-12-31
IL185909A0 (en) 2008-01-06
ATE496911T3 (de) 2011-02-15
US7888362B2 (en) 2011-02-15
US20110152286A1 (en) 2011-06-23
US9839637B1 (en) 2017-12-12
PL1869025T6 (pl) 2017-10-31
US9206167B2 (en) 2015-12-08
LUC00086I2 (oth) 2018-11-26
ES2358631T7 (es) 2016-11-17
HUS1800041I1 (hu) 2018-11-28
CN101155804B (zh) 2013-03-27
AU2006237905B2 (en) 2009-09-03
EP1869025B3 (en) 2016-08-31
EP1869025B1 (en) 2011-01-26
US20200237755A1 (en) 2020-07-30
IL185909A (en) 2014-08-31
CN101155804A (zh) 2008-04-02
US8618109B2 (en) 2013-12-31
KR100937623B1 (ko) 2010-01-20
HK1112236A1 (en) 2008-08-29
US20190117648A1 (en) 2019-04-25
NL300946I2 (nl) 2018-09-26
US8349840B2 (en) 2013-01-08
CY2018028I2 (el) 2019-07-10
US20170231983A1 (en) 2017-08-17
TWI320783B (en) 2010-02-21
ES2358631T3 (es) 2011-05-12
US20160051548A1 (en) 2016-02-25
LTPA2018509I1 (lt) 2018-09-10
CY1111206T1 (el) 2015-06-11
SI1869025T1 (sl) 2011-04-29
IN2012DN00855A (oth) 2015-07-10
US20170368060A1 (en) 2017-12-28
CY2018028I1 (el) 2019-07-10
US9480686B2 (en) 2016-11-01
AU2006237905C1 (en) 2015-11-19
HUE011611T6 (en) 2017-04-28
US20210113556A1 (en) 2021-04-22
EP1869025A1 (en) 2007-12-26
DE602006019838D1 (de) 2011-03-10
US20140163039A1 (en) 2014-06-12
DK1869025T3 (da) 2011-04-04
AR053577A1 (es) 2007-05-09
KR20080002817A (ko) 2008-01-04
USRE48059E1 (en) 2020-06-23
FR18C0004I1 (fr) 2018-11-02
US20100179322A1 (en) 2010-07-15
CA2602247C (en) 2013-04-02
PT1869025E (pt) 2011-02-04
US20170000786A1 (en) 2017-01-05
BRPI0609785A2 (pt) 2010-04-27

Similar Documents

Publication Publication Date Title
FR18C0004I2 (fr) Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1601251A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP1993589A4 (en) TREATMENTS FOR NEUROLOGICAL DISEASES
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
EP2470553A4 (en) POLYHYDROYLATED GALLEN ACID FOR THE TREATMENT OF GALLERY DISEASES
ZA200903772B (en) Treatment of pervasive developmental disorders
EP2618826A4 (en) PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISEASES
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
EP2311472A4 (en) MEANS TO REDUCE COGNITIVE INTERFERENCE
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
EP2474544A4 (en) THERAPEUTIC ACTIVE FOR FARES
EP2219447A4 (en) S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF UTERUS HYPERCONTACTILITY DISORDERS
EP1732549A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
EP2026659A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
EP1734957A4 (en) THIAZOLE SULFAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP2231558A4 (en) 3,4-SUBSTITUTED PYRROLIDIN BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
FR2887785B1 (fr) Dispositif pour le traitement de substances organiques
TWI340643B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders